The Sweden Gastrointestinal Stent Market was valued at $5.81 Million in 2026 and projected to reach to $7.13 Million by 2031, representing a compound annual growth rate of 4.2%. Sweden's gastrointestinal stent market is positioned for steady growth driven by the country's robust healthcare infrastructure and increasing prevalence of GI disorders among its aging population.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Sweden's gastrointestinal stent market is valued at USD 5.81 million in 2026, with projected growth to USD 7.13 million by 2031, reflecting steady market expansion.
The Swedish market demonstrates a CAGR of 4.2% from 2026 to 2031, outpacing some European peers while remaining below the global average of 5.7%, indicating moderate but consistent demand.
Sweden's advanced healthcare system and high adoption of minimally invasive procedures support strong demand for gastrointestinal stents across hospitals and specialized clinics.
Sweden's aging demographic profile increases prevalence of gastrointestinal disorders, creating sustained demand for stent interventions and supporting long-term market growth.
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | BIODEGRADABLE STENTS (Type) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 5.7% from 2026 to 2031 |
| Largest Segment | HOSPITALS & CLINICS (End User) |
| Market Size Base Year (Billions) | ~USD 0.62 (2026) |
| Revenue Forecast (Billions) | ~USD 0.82 (2031) |
| Segments Covered | Product, Type, Mechanism, Coverage, Application, End User |
6 segment dimensions are covered across the global market.
| Segment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| AMBULATORY SURGICAL CENTERS | 0.55 | 0.58 | 0.6 | 0.63 | 0.66 | 0.69 | 0.72 | 0.76 | 4.7 |
| HOSPITALS & CLINICS | 3.66 | 3.79 | 3.92 | 4.07 | 4.22 | 4.39 | 4.56 | 4.75 | 3.9 |
| SPECIALTY ENDOSCOPY CENTERS/GI CLINICS | 1.18 | 1.23 | 1.28 | 1.34 | 1.41 | 1.47 | 1.55 | 1.62 | 4.8 |
| TOTAL | 5.39 | 5.59 | 5.81 | 6.04 | 6.29 | 6.55 | 6.83 | 7.13 | 4.2 |
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| ATS AUTOMATION TOOLING SYSTEMS INC | Canada | Public Company | Custom automated manufacturing and assembly systems,Pre- and post-automation services and lifecycle support,Contract manufacturing and integration services, |
| BOSTON SCIENTIFIC CORPORATION | United States | Public Company | Cardiovascular (coronary, structural heart, CRM, peripheral),MedSurg – Endoscopy (GI, pancreaticobiliary, infection prevention),MedSurg – Urology and Pelvic Health, |
| OLYMPUS CORPORATION | Japan | Public Company | Gastrointestinal Solutions (endoscopes, devices, services),Surgical Endoscopes & Integrated OR Solutions,Advanced Energy Devices, |
| M.I. TECH | Malaysia | Public Company | Die sorting and smart binning equipment,Test handling and vision inspection equipment,Laser bonding and precision bonding equipment, |
| MICRO-TECH (NANJING) CO., LTD. | China | Public Company | Digestive endoscopy – ESD and ERCP (therapeutic devices and accessories),Stents and dilation/biopsy systems (biliary, intestinal, esophageal),Hemostasis, EUS, and diagnostic accessories, |
| MERIT MEDICAL SYSTEMS | United States | Public Company | Cardiovascular access and intervention (micropuncture, sheaths, guidewires, angiography, hemostasis),Peripheral intervention and embolotherapy (angiography, drainage, delivery, embolic solutions),Oncology and spine (soft tissue biopsy, vertebral augmentation, RF ablation, bone biopsy), |
| MEDTRONIC | Ireland | Public Company | Cardiovascular Portfolio,Neuroscience Portfolio,Medical Surgical Portfolio, |
| STERIS | Ireland | Public Company | Healthcare sterilization, decontamination, and OR infrastructure,Applied Sterilization Technologies (outsourced sterilization services),Life sciences contamination control and processing, |
| BD | United States | Public Company | Medical Essentials (IV access, syringes, needles, sharps, vascular care),Connected Care (infusion systems, medication management, pharmacy automation, informatics),BioPharma Systems (prefillable drug delivery systems), |
| Q3 MEDICAL GROUP | Ireland | Private Company | Specialty procedures and interventions,Outpatient and ambulatory services,Diagnostics and imaging, |
| BVM | Tunisia | Public Company | Fire, miscellaneous accidents, and engineering,Marine, energy, and aviation (including pools),Agricultural and emerging risks, |
ATS Automation Tooling Systems Inc is a Canadian public company founded in 1978 that employs 7,000 people. The company specializes in automation and tooling systems.
Boston Scientific Corporation is a United States-based public company founded in 1979 with 59,000 employees. The company operates in the medical device and healthcare sectors.
Olympus Corporation is a Japanese public company founded in 1919 with 28,138 employees. The company operates across imaging, medical, and industrial technology sectors.
M.I. Tech is a Malaysian public company founded in 2007 with 594 employees. The company operates in the technology sector.
Micro-Tech (Nanjing) Co., Ltd. is a Chinese public company founded in 2000 with 2,433 employees. The company operates in the medical device industry.
Merit Medical Systems is a United States-based public company founded in 1987 with 7,500 employees. The company manufactures and distributes medical devices and supplies.
Medtronic is an Ireland-based public company founded in 1949 with 95,000 employees. The company is a global leader in medical technology, services, and solutions.
STERIS is an Ireland-based public company founded in 1985. The company provides sterilization and contamination control solutions for healthcare and industrial markets.
BD is a United States-based public company founded in 1897 with 72,000 employees. The company is a global medical technology company specializing in medical devices, diagnostics, and biosciences.
Q3 Medical Group is an Ireland-based private company founded in 2013. The company operates in the medical device or healthcare sector.
BVM is a Tunisia-based public company founded in 1981 with 99 employees. The company operates in the medical or industrial sector.
Sweden's gastrointestinal stent market is valued at USD 5.81 million in 2026, based on verified market data.
Sweden's gastrointestinal stent market is projected to reach USD 7.13 million by 2031, representing growth from the 2026 baseline.
Sweden's gastrointestinal stent market is expected to grow at a CAGR of 4.2% between 2026 and 2031.
Sweden's market growth is driven by an aging population, advanced healthcare infrastructure, strong reimbursement policies, and increasing adoption of minimally invasive endoscopic procedures.
Sweden's healthcare providers primarily utilize self-expanding metal stents (SEMS) and plastic stents for biliary and esophageal applications, supported by robust clinical guidelines.
This research study extensively utilized both primary and secondary sources. It involved analyzing various factors influencing the industry to identify segmentation types, industry trends, key players, the competitive landscape, key market dynamics, and strategies employed by key players.
This research study utilized a variety of comprehensive secondary sources, including directories; databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings from various companies. Secondary research was employed to gather information crucial for an in-depth, technical, market-oriented, and commercial analysis of the gastrointestinal stent market. This approach also helped identify key players in the industry and allowed for classification and segmentation based on emerging trends at the most detailed level. Furthermore, significant developments pertaining to both market and technological perspectives were documented. A database of primary industry leaders was created as part of this secondary research.
In the primary research process, we interviewed a range of sources from both the supply and demand sides to gather qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the gastrointestinal stent market. Primary sources from the demand side include gastroenterologists, interventional endoscopists, and surgeons from hospitals and ambulatory surgical centers, as well as directors of endoscopy units and gastrointestinal clinics.
A breakdown of the primary respondents is provided below:
Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.
Note 2: Other designations include sales, marketing, and product managers.
Note 3: Tiers are defined based on a company’s total revenue. As of 2025: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
The total size of the gastrointestinal stent market was determined through data triangulation using three approaches, as outlined below. After each approach, the weighted average of the three approaches was calculated based on the level of assumptions used in each.

After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed where applicable to complete the overall market engineering process and derive the exact statistics for all segments and subsegments.
The gastrointestinal stent market comprises medical devices designed for the minimally invasive management of obstructions, strictures, leaks, and fistulas within the gastrointestinal tract, including the esophagus, stomach, intestines, and biliary system. These stents, primarily self-expanding metal, plastic, and biodegradable variants, are deployed endoscopically or fluoroscopically to restore luminal patency, enable fluid drainage, and support tissue healing in both malignant and benign conditions. The market includes products, delivery systems, and associated technologies used across hospitals, ambulatory surgical centers, and specialty clinics, with applications spanning oncology, post-surgical complications, and chronic gastrointestinal disorders, driven by the growing preference for minimally invasive treatment approaches and improved patient outcomes.
With the market data provided, MarketsandMarkets offers customizations to meet your company’s specific needs. The following customization options are available for the report:
Full forecast, segment splits, and company analysis for all Gastrointestinal Stent Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report